Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Oral medicine and oral cancer

No studies found 2 · 66.7%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
The trials did not measure costs.
0 studies
No studies found

Cost (mean per-patient supportive care costs) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
Mean per-patient supportive care costs lower with amifostine (USD 4401) than control (USD 5873); P = 0.02 (Buntzel 1998 / Bennett 2001)
1 study · 28 participants
GRADE not reported

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
0 studies
No studies found